Aurora Cannabis

Aurora Cannabis’s board unanimously recommends rejecting Curaleaf’s unsolicited takeover offer after a special committee and advisers reviewed the proposal. Aurora highlights its cash balance of USD 149 million and debt-free status as of June 30, 2026, while Curaleaf carries more than USD 1 billion of debt and lease liabilities. The proposed share-exchange ratio would give Aurora shareholders about 7.7% of the combined company but only roughly 3.2% of the voting rights. TD Securities considers the offer undervalued; shareholders are urged not to tender their shares or to withdraw any shares already tendered. » More on de.investing.com

Aurora Cannabis is buying 100% of Internode Pharma and HAP Pharma for £2.1 million in cash, gaining a licensed import and distribution hub and a virtual pharmacy in Birmingham. The acquisition gives Aurora direct control of the medical cannabis supply chain in the UK and targets growth in the British market. Payment is subject to closing conditions; Aurora expects the deal to contribute to adjusted EBITDA over time through operational efficiencies and reduced reliance on third parties. » More on de.investing.com

Aurora Cannabis has received an unsolicited takeover offer from Curaleaf and recommends that shareholders take no action for the time being. Curaleaf’s bid values Aurora at $4.00 per share (0.3463 Curaleaf shares plus $0.75 in cash) with an upside cap of $5.00 per share. The board formed an independent special committee to review the offer with advisers and to issue a recommendation within 15 days; the offer period runs for at least 105 days until at least December 1, 2026. CEO Miguel Martin accuses Curaleaf of primarily trying to acquire Aurora’s EU‑GMP production facilities and medical platforms at a bargain price. » More on de.investing.com